April 8, 2021
Online Livestream
Summit
REMS VirtualSummit
Next-Gen Partnership & Technology Strategies to Advance Drug Safety Programs
Days
Hours
Minutes
Seconds

Risk management is an ever-changing process and there is always room for reassessing and improving your REMS approach. In particular, better standardization is needed more urgently than ever. The need for better standardization is of urgent importance for REMS professionals. To address these and other ever-present questions, DGE invites you to attend its REMS Virtual Summit, streaming online April 8-9, 2021. During this intense skill-builder, all industry stakeholders will unite to enhance your understanding of REMS best practices, inclusion criteria, and submission methods. Through our proven interactive online platform, you’ll learn everything you need about assessing benefit-risk balance and evaluating the procedures for successful submissions.

Top Reasons to Attend
  • Deep dive into the full REMS life cycle
  • Discover pitfalls of negotiating with the FDA
  • Address challenges of working with the added time constraints needed for an ETASU
  • Clear analysis for engaging external stakeholders
  • Ensure proper management and coordination REMS submissions
  • Minimize barriers for REMS standardization
Who Should Attend

This event is designed for pharmaceutical, biotech, and medical device professionals responsible for:

  • Clinical Risk Management
  • Drug / Product Safety
  • Quality Assurance
  • Surveillance
  • Pharmacovigilance
  • Benefit / Risk Management
  • REMS
  • Clinical Data Management
  • Clinical Operations
  • Clinical Affairs
  • Legal
  • Regulatory Affairs / Compliance
  • Medical Direction
  • Life Cycle Management
  • Epidemiology / Pharmacoepidemiology

This Program Is Also Of Interest To:

  • Technology vendors
  • Data management services
  • Pharmacovigilance / drug surveillance specialists
  • Drug safety service providers
  • REMS service providers
  • CROs
Conference
New Topics
Featured Speakers
Bob Anders
AKEBIA THERAPEUTICS
Senior Scientific Director, Clinical Development
Carmit Strauss
AMGEN
Director, Global Safety (Benefit Risk Management Officer)
Deborah Collyar
PAIR: PATIENT ADVOCATES IN RESEARCH
Founder and President
Jacqueline Gerena, MBA
Aimmune Therapeutics
Director, Program Management and Women of Color in Pharma Board Member
John Klimek
John Klimek
NATIONAL COUNCIL FOR PRESCRIPTION DRUG PROGRAMS (NCPDP)
Sr VP Standards and Information Technology
Kal Elhoregy
AMNEAL PHARMACEUTICALS
Director
Kevin Holman
JANSSEN
Director, REMS and Risk Management Center of Excellence
Khaudeja Bano
ABBOTT
Head of Medical Affairs
Kishore Gopu
TEVA
Director
Michele Davidson
WALGREENS
Senior Manager, Pharmacy Technical Standards Development & Policy, Government Relations
Reema Mehtah
PFIZER
Head of Risk Management and Safety Surveillance Research
Suzanne Marinello
OTSUKA PHARMACEUTICALS
Associate Director, REMS and Patient Support
Toyin Adewole
SUPERNUS PHARMACEUTICALS
Associate Director, Drug Safety
Event Schedule
All Times are in Eastern Standard Time          

REMS managers face constant but predictable challenges, and must always be prepared to hurdle them.  This session works through an overview and effective strategies for different REMS Elements to Assure Safe Use (ETASU).

  • Evaluate the essentials of a REMS program
  • Set manageable goals to hit timeline markers and budgets
  • Tackle the continuous issues head-on=

A shared system can significantly reduce the burden for stakeholders across the REMS. Developing a shared REMS requires first clarifying internal and external strategies.

  • Assess the development process for a shared system REMS
  • Leverage the NCPDP standards in REMS
  • Review current procedures and methods
  • Discuss next steps towards implementation and adoption

Sudden and unpredictable challenges can occur at any turn.  You will be best-suited for your own REMS program by learning from others who confronted the toughest issues and overcame them. 

  • Navigate issues that can go awry at any time during the REMS life cycle
  • Discuss case studies from those in the thick of the REMS system
  • Hear issues that you can come across that aren’t in the guidelines

FDA may require ETASU for a product associated with serious risks.  What are the most effective and reliable way for you to navigate these additional steps?  

  • Address challenges of working with the added time constraints needed for an ETASU
  • Budget the additional ETASU costs to ensure manufacturers develop and operate these systems safely
  • Make sure the ETASU does not excessively burden patient access

Despite ongoing standardization, many REMS continue to utilize unique or non-standard elements or processes. Explore past experience and case studies when it comes to negotiating with the FDA.

  • Discuss common challenges during the NDA
  • Tackle issues faced from various NDAs
  • Address key areas for alignment  during REMS negotiations with FDA

There are multiple new Task Group initiatives under way with specialty pharmacy and payers.  Keeping track of these new developments can help set up your REMS for success.

  • Tackle new standards of Real-Time Prescription Benefit
  • Hear the National Council for Prescription Drug Programs speak to the information needed to prescribers of REMS drugs
  • Address the Electronic Prior Authorization work side-by-side with REMS as many insurers/payers now require this

Organizing and preparing throughout REMS development can help you ensure the satisfactory documentation required.  You and your teams will have to develop CAPAs that implement best practice and address any areas of noncompliance. 

  • Ensure your Audit Plan is comprehensive and actionable
  • Explore challenges and solutions related to program noncompliance
  • Build effective communication techniques with the FDA about noncompliance and CAPAs
All Times are in Eastern Standard Time          

REMS programs are complex endeavors, requiring input and participation from diverse teams within your company, external participants in the program, and often vendors. This session focuses on building streamlined and efficient methods for engagement among both cross-functional teams and external participants.

  • Build an effective internal coalition to build and manage REMS
  • Discuss best practices for engaging external stakeholders (i.e., patients, prescribers, pharmacies, and distributors)
  • Allocate stakeholder responsibility for requirements
  • Craft meaningful and effective communications to address risk

Your strategy needs to include effective training for pharmacies and addressing product risk through them.  This session addresses REMS standardization from a pharmacy point of view.  

  • Highlight effective training and pharmacy compliance management
  • Initiate appropriate data and pharmacy requirements
  • Efficiently keep up with policies and procedures

REMS programs are difficult enough in themselves – but implementing a shared system has another level of challenges teams must overcome.  

  • Delegate responsibilities and duties 
  • Hear how to apply, maintain and tackle issues that come with sharing a REMS database and infrastructure
  • Ensure proper timing of submissions
  • Coordinate editing efforts with your single REMS doc and materials 

Mergers and acquisitions commonly occur in the pharmaceutical industry.  Through proper planning for the uncertainty around these changes, you can make sure your REMS programs are not adversely impacted.

  • Review a recent merger case study, featuring pitfalls and lessons learned
  • Adapt and assimilate to your next merger
  • Navigate the new and old internal partner roles

Patients are uniquely positioned to inform the understanding of the therapeutic context for drug development and evaluation. As experts in living with a specific condition, the patient and their perspective are critical to REMS success.

  • Collect and utilize patient-focused approaches in drug development and regulatory decision-making
  • Understand how to capture the patient voice
  • Create an effective checklist with the patient in mind
  • Outline risk assessment and treatment benefits with the patient first mentality 
  • Communicate information that supports their decision-making

Engaging patients can influence research to be more patient centered, useful, and trustworthy and ultimately lead to greater use and uptake of research results by the patient and broader healthcare community

  • Optimize and conduct patient benefit–risk assessment 
  • Achieve rapid market penetration and product uptake
  • Review best practices for creating simple and detailed materials for REMS patients to easily read, understand and apply

Technologies upcoming in 2021 and beyond can help ensure your REMS is effectively implemented and assessed.  These new approaches and others will drive REMS programs into the future.

  • Explore new technology and tools that can increase efficiency of drug distribution
  • Apply techniques that will ensure safety
  • Guarantee patients have all the information for medication distribution and use
Register Now

This window is secured by 256 bit encryption on a PCI compliant network. Click here to view this window in its own page.

Subscribe to Conference Updates
Join our e-newsletter list to follow closely all news.
Event Sponsors
15
Speakers
21
Days
251
Participants
125
Workshops
90
Venue
Contact Us